scholarly journals Effects of a changeover from other angiotensin II receptor blockers to olmesartan on left ventricular hypertrophy in heart failure patients

2016 ◽  
Vol 32 (5) ◽  
pp. 584-590 ◽  
Author(s):  
Hiroyuki Shimoura ◽  
Hidekazu Tanaka ◽  
Kensuke Matsumoto ◽  
Yasuhide Mochizuki ◽  
Yutaka Hatani ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Left Ventricular ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Heart Failure Patients ◽  
Receptor Blockers

scholarly journals Left Ventricular Hypertrophy – the Problem and Possible Solutions

2005 ◽  
Vol 33 (1_suppl) ◽  
pp. 3A-11A ◽  
Author(s):  
P Gosse
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Left Ventricular Hypertrophy ◽  
Ventricular Hypertrophy ◽  
Structural Changes ◽  
Target Organ Damage ◽  
Left Ventricular ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Receptor Blockers

Left ventricular hypertrophy (LVH), which describes pathological changes in cardiac structure, is a powerful and reversible predictor of cardiovascular risk. There is a continuous relationship between left ventricular mass (LVM) and the likelihood of cardiovascular events, with no cut-off between the absence of such events and heightened risk. A correlation between LVH and blood pressure is well established. There is a paradox, however, that the structural changes to the heart as a result of increased workload due to high blood pressure appear to promote cardiovascular disease. This may be partially explained by the fact that ambulatory blood pressure measurements correlate more closely with LVH than resting blood pressure. Blood pressure variation throughout the day is also emerging as an important correlate of LVH, and a strong association has been identified between an early morning rise in blood pressure and increased LVM. Use of anti-hypertensive agents not only lowers blood pressure, but can also bring about LVH regression. The pathological role of angiotensin II in LVH and target-organ damage within the cardiovascular continuum suggest that agents targeting the renin – angiotensin - aldosterone system (RAAS), such as the angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, may prove particularly effective and may confer beneficial effects in addition to the lowering of blood pressure. The angiotensin II receptor blockers may be very appropriate treatment options because of their placebo-like tolerability and the possibility of more complete blockade of the RAAS. Within this class of anti-hypertensive agents, pharmacological differences may mean that some agents afford greater cardioprotection than others.

The Use of Angiotensin-II Receptor Blockers in Heart Failure

2002 ◽  
Vol 15 (4) ◽  
pp. 318-325
Author(s):  
Jodie M. Fink
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Enzyme Inhibitors ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Converting Enzyme Inhibitors ◽  
Heart Failure Patients ◽  
Patients With Heart Failure ◽  
Receptor Blockers

Angiotensin-II receptor blockers (ARBs) have recently been evaluated in large trials to determine their role in the treatment of heart failure. It is clear that angiotensin-converting enzyme inhibitors (ACE-Is) prevent the effects of an overactive renin-angiotensin aldosterone system and therefore prevent disease progression. Despite this evidence, intolerance (eg, cough) limits the use of ACE-Is in heart failure patients. Improved tolerability makes ARBs attractive alternatives in patients intolerant to ACE-Is. ARBs are also hypothesized to have additional benefits when used in combination with ACE-Is through more complete inhibition of angiotensin-II. However, studies of ARBs in patients with heart failure have not confirmed this hypothesis. This article describes the rationale and evaluates the literature for the use of ARBs in heart failure.

Dosage of angiotensin-II receptor blockers in heart failure patients following changes in Danish drug reimbursement policies

2014 ◽  
Vol 23 (12) ◽  
pp. 1281-1287
Author(s):  
Christian Selmer ◽  
Morten Lamberts ◽  
Søren Lund Kristensen ◽  
Lene Mia von Kappelgaard ◽  
Lars Køber ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Angiotensin Ii Receptor Blockers ◽  
Angiotensin Ii Receptor ◽  
Drug Reimbursement ◽  
Heart Failure Patients ◽  
Receptor Blockers

scholarly journals Angiotensin II receptors blockers in the treatment of patients with cardiorenal syndrome

2015 ◽  
Vol 96 (6) ◽  
pp. 1010-1014
Author(s):  
A A Nasybullina ◽  
O V Bulashova ◽  
E V Khazova ◽  
V M Gazizyanova ◽  
M I Malkova
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Left Ventricular ◽  
Kidney Damage ◽  
Angiotensin Ii Receptor Blockers ◽  
Left Ventricular Ejection ◽  
Angiotensin Ii Receptors ◽  
Angiotensin Ii Receptor ◽  
Cardiac Pathology ◽  
Receptor Blockers

Literature review on the use of angiotensin II receptors blockers in patients with combined pathology of the cardiovascular and renal systems: chronic heart failure and chronic kidney disease is presented. The angiotensin II receptors blockers positive effect is determined by the selective and complete type 1 receptors blockade and simultaneous stimulation of the type 2 receptors. On the one hand angiotensin II blockers are well-studied and widely used class of drugs in patients with cardiac pathology. On the other hand, the efficacy and safety of this drugs group in patients with renal impairment due to cardiac pathology or coexisting urinary system diseases are not well studied. Clinical studies have confirmed the angiotensin II receptor blockers pharmacotherapeutic activity and safety in reducing the cardiovascular events rate, including cardiovascular mortality, myocardial infarction, stroke, number of hospitalizations due to decompensated heart failure. There is data regarding the heart failure poor prognosis in decreased kidney function, but most of these studies were conducted in patients with end-stage renal failure. Data on angiotensin II receptor blockers effect on the course and prognosis of patients with heart failure in association with kidney damage is not enough. The effect of angiotensin II on the heart failure clinical presentation and outcomes according to the left ventricular ejection fraction preservation or reduction, and on the severity of kidney damage is not studied.

Sign in / Sign up

Export Citation Format

Share Document